Original Source(s)
Related Content
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.
July 1, 2026
-
1 min
ACS report: Lung cancer deaths plunge as survival doubles
Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.
September 28, 2026
-
6 min